Logo image of PKI

PERKINELMER INC (PKI) Stock Fundamental Analysis

NYSE:PKI - US7140461093 - Common Stock

115.24 USD
-1.06 (-0.91%)
Last: 5/15/2023, 8:04:00 PM
115.24 USD
0 (0%)
After Hours: 5/15/2023, 8:04:00 PM
Fundamental Rating

5

PKI gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. PKI scores excellent on profitability, but there are some minor concerns on its financial health. PKI is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

PKI had positive earnings in the past year.
PKI had a positive operating cash flow in the past year.
Each year in the past 5 years PKI has been profitable.
Each year in the past 5 years PKI had a positive operating cash flow.
PKI Yearly Net Income VS EBIT VS OCF VS FCFPKI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B

1.2 Ratios

The Return On Assets of PKI (5.28%) is better than 76.19% of its industry peers.
Looking at the Return On Equity, with a value of 10.11%, PKI is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.49%, PKI is in the better half of the industry, outperforming 73.02% of the companies in the same industry.
PKI had an Average Return On Invested Capital over the past 3 years of 52.37%. This is significantly above the industry average of 16.00%.
The 3 year average ROIC (52.37%) for PKI is well above the current ROIC(6.49%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 5.28%
ROE 10.11%
ROIC 6.49%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)52.37%
ROIC(5y)N/A
PKI Yearly ROA, ROE, ROICPKI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 5 10 15

1.3 Margins

PKI has a better Profit Margin (16.32%) than 82.54% of its industry peers.
PKI's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 23.43%, PKI belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
PKI's Operating Margin has improved in the last couple of years.
PKI's Gross Margin of 58.39% is fine compared to the rest of the industry. PKI outperforms 76.19% of its industry peers.
In the last couple of years the Gross Margin of PKI has grown nicely.
Industry RankSector Rank
OM 23.43%
PM (TTM) 16.32%
GM 58.39%
OM growth 3Y19.66%
OM growth 5Y11.6%
PM growth 3Y29.61%
PM growth 5Y5.8%
GM growth 3Y7.46%
GM growth 5Y4.78%
PKI Yearly Profit, Operating, Gross MarginsPKI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PKI is creating value.
PKI has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, PKI has an improved debt to assets ratio.
PKI Yearly Shares OutstandingPKI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
PKI Yearly Total Debt VS Total AssetsPKI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 5B 10B 15B

2.2 Solvency

PKI has an Altman-Z score of 2.51. This is not the best score and indicates that PKI is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of PKI (2.51) is comparable to the rest of the industry.
The Debt to FCF ratio of PKI is 7.40, which is on the high side as it means it would take PKI, 7.40 years of fcf income to pay off all of its debts.
PKI has a better Debt to FCF ratio (7.40) than 77.78% of its industry peers.
A Debt/Equity ratio of 0.53 indicates that PKI is somewhat dependend on debt financing.
PKI has a worse Debt to Equity ratio (0.53) than 68.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 7.4
Altman-Z 2.51
ROIC/WACC0.65
WACC10.02%
PKI Yearly LT Debt VS Equity VS FCFPKI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B

2.3 Liquidity

A Current Ratio of 2.13 indicates that PKI has no problem at all paying its short term obligations.
The Current ratio of PKI (2.13) is worse than 68.25% of its industry peers.
PKI has a Quick Ratio of 1.87. This is a normal value and indicates that PKI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PKI (1.87) is worse than 65.08% of its industry peers.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.87
PKI Yearly Current Assets VS Current LiabilitesPKI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

More info and screens

2

3. Growth

3.1 Past

PKI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.47%.
PKI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.15% yearly.
Looking at the last year, PKI shows a decrease in Revenue. The Revenue has decreased by -3.37% in the last year.
The Revenue has been growing slightly by 7.97% on average over the past years.
EPS 1Y (TTM)-30.47%
EPS 3Y24.65%
EPS 5Y22.15%
EPS Q2Q%-33.59%
Revenue 1Y (TTM)-3.37%
Revenue growth 3Y4.72%
Revenue growth 5Y7.97%
Sales Q2Q%-27.89%

3.2 Future

PKI is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.04% yearly.
Based on estimates for the next years, PKI will show a decrease in Revenue. The Revenue will decrease by -8.60% on average per year.
EPS Next Y-34.36%
EPS Next 2Y-12.79%
EPS Next 3Y-4.57%
EPS Next 5Y6.04%
Revenue Next Year-31.32%
Revenue Next 2Y-15.11%
Revenue Next 3Y-8.6%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PKI Yearly Revenue VS EstimatesPKI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B
PKI Yearly EPS VS EstimatesPKI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6 8 10

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.51 indicates a correct valuation of PKI.
96.83% of the companies in the same industry are more expensive than PKI, based on the Price/Earnings ratio.
PKI's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.08.
PKI is valuated rather expensively with a Price/Forward Earnings ratio of 22.11.
Based on the Price/Forward Earnings ratio, PKI is valued a bit cheaper than 77.78% of the companies in the same industry.
PKI's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.72.
Industry RankSector Rank
PE 14.51
Fwd PE 22.11
PKI Price Earnings VS Forward Price EarningsPKI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PKI is valued cheaply inside the industry as 93.65% of the companies are valued more expensively.
PKI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PKI is cheaper than 87.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.52
EV/EBITDA 12.35
PKI Per share dataPKI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

The excellent profitability rating of PKI may justify a higher PE ratio.
PKI's earnings are expected to decrease with -4.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.66
EPS Next 2Y-12.79%
EPS Next 3Y-4.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PKI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PERKINELMER INC

NYSE:PKI (5/15/2023, 8:04:00 PM)

After market: 115.24 0 (0%)

115.24

-1.06 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-11 2023-05-11/bmo
Earnings (Next)07-31 2023-07-31/bmo
Inst Owners86.56%
Inst Owner Change-9.19%
Ins Owners0.81%
Ins Owner Change0%
Market Cap14.57B
Analysts73
Price Target159.39 (38.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP4.74%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.02%
Min EPS beat(2)2.33%
Max EPS beat(2)3.7%
EPS beat(4)4
Avg EPS beat(4)8.57%
Min EPS beat(4)2.33%
Max EPS beat(4)14.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-29.78%
Min Revenue beat(2)-30.42%
Max Revenue beat(2)-29.14%
Revenue beat(4)2
Avg Revenue beat(4)-0.3%
Min Revenue beat(4)-30.42%
Max Revenue beat(4)52.86%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.68%
PT rev (3m)-2.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.24%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.39%
Valuation
Industry RankSector Rank
PE 14.51
Fwd PE 22.11
P/S 3.19
P/FCF 24.52
P/OCF 21.43
P/B 1.97
P/tB N/A
EV/EBITDA 12.35
EPS(TTM)7.94
EY6.89%
EPS(NY)5.21
Fwd EY4.52%
FCF(TTM)4.7
FCFY4.08%
OCF(TTM)5.38
OCFY4.67%
SpS36.16
BVpS58.4
TBVpS-19.59
PEG (NY)N/A
PEG (5Y)0.66
Profitability
Industry RankSector Rank
ROA 5.28%
ROE 10.11%
ROCE N/A
ROIC 6.49%
ROICexc 6.74%
ROICexgc 35.96%
OM 23.43%
PM (TTM) 16.32%
GM 58.39%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)52.37%
ROIC(5y)N/A
ROICexc(3y)8.57%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0.99%
ROICexcg growth 5Y-8%
ROICexc growth 3Y-3.25%
ROICexc growth 5Y0.67%
OM growth 3Y19.66%
OM growth 5Y11.6%
PM growth 3Y29.61%
PM growth 5Y5.8%
GM growth 3Y7.46%
GM growth 5Y4.78%
F-Score7
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.53
Debt/FCF 7.4
Debt/EBITDA 2.93
Cap/Depr 20.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 79.63%
Current Ratio 2.13
Quick Ratio 1.87
Altman-Z 2.51
F-Score7
WACC10.02%
ROIC/WACC0.65
Cap/Depr(3y)26.47%
Cap/Depr(5y)33.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)118.43%
Profit Quality(5y)114.16%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.47%
EPS 3Y24.65%
EPS 5Y22.15%
EPS Q2Q%-33.59%
EPS Next Y-34.36%
EPS Next 2Y-12.79%
EPS Next 3Y-4.57%
EPS Next 5Y6.04%
Revenue 1Y (TTM)-3.37%
Revenue growth 3Y4.72%
Revenue growth 5Y7.97%
Sales Q2Q%-27.89%
Revenue Next Year-31.32%
Revenue Next 2Y-15.11%
Revenue Next 3Y-8.6%
Revenue Next 5YN/A
EBIT growth 1Y-24.58%
EBIT growth 3Y25.31%
EBIT growth 5Y20.49%
EBIT Next Year-23.7%
EBIT Next 3Y-3.21%
EBIT Next 5Y3.97%
FCF growth 1Y-54.67%
FCF growth 3Y28.17%
FCF growth 5Y18.96%
OCF growth 1Y-51.81%
OCF growth 3Y23.2%
OCF growth 5Y18.7%